Atrial Fibrillation and Cancer: a Nationwide French Cohort Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05563883

Enrollment

5000000

Registered

2022-10-03

Start date

2022-09-22

Completion date

2030-01-31

Last updated

2022-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation, Bleeding, Cancer, Thromboembolism

Brief summary

Atrial fibrillation (AF) is a common complication associated with cancer but the risk of AF according to the cancer localization and status as well as the risk of thromboembolisms, bleedings and mortality are poorly known. The objective of this study is to use a very large French nationwide cohort to adress thèses questions.

Interventions

OTHERevent occurence

occurence of an event of interest: (AF, cancer, thromboembolism, bleeding, mortality...

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* adult hospitalized patients * with an ICD-10 code discharge from january 2010 to december 2019 in the French national hospital discharge database (PMSI Programme de Médicalisation des Systèmes d'Information)

Exclusion criteria

* children

Design outcomes

Primary

Measure	Time frame	Description
atrial fibrillation	from inclusion in the cohort up to 10 years	occurrence of atrial fibrillation
cancer	ffrom inclusion in the cohort up to 10 years	occurrence of cancer

Secondary

Measure	Time frame	Description
thromboembolism	from inclusion in the cohort up to 10 years	occurrence of thromboembolism
bleeding	from inclusion in the cohort up to 10 years	occurrence of bleeding
mortality	from inclusion in the cohort up to 10 years	occurrence of mortality

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026